This is a guide to accompany the ACMA Medical Affairs & MSL Power Play Series: Part 1 webinar with ACMA.

In 2025, the role of Medical Science Liaisons (MSLs) is undergoing a profound transformation, driven by evolving industry dynamics, emerging technologies, and a fluid global healthcare environment. The Accreditation Council for Medical Affairs (ACMA) has identified five dominant trends shaping the future of MSLs and medical affairs professionals: the emphasis on rare disease and specialty areas, the integration of ethical AI, harmonization and standardization within organizations, the importance of real-world evidence, and patient-centric engagement. Each of these trends reflects the expanding strategic significance of MSLs across the pharmaceutical and healthcare ecosystem.

1. Growing Emphasis on Rare Diseases and Specialty Therapeutics

A primary trend is the increasing focus on rare diseases and specialty therapeutics. This shift is driven by a significant rise in FDA-approved drugs targeting rare conditions, which often come with unique market and clinical challenges. MSLs must adapt by expanding their competencies to engage diverse stakeholders, including regulatory agencies, payers, clinicians, and patient advocacy groups, with nuanced, science-based communication.

Because these therapeutic areas involve smaller patient populations and fewer treating physicians, traditional performance metrics such as the number of healthcare professional interactions may not be appropriate. Instead, companies are pivoting toward qualitative metrics that demonstrate the impact and value MSLs deliver in these niche areas. Additionally, rare disease drug development demands a sophisticated understanding of clinical trial design, especially due to difficulties in patient recruitment and statistical power in small populations.

Moreover, product launches in these fields are high-risk. A recent Deloitte study underscores that well-prepared medical affairs teams significantly improve launch success rates. MSLs with expertise in rare diseases are often compensated more competitively, reflecting the value and expertise they bring to organizational success in this space.

2. The Rise of Ethical AI and Responsible Innovation

Artificial Intelligence (AI) is revolutionizing the pharmaceutical landscape, and MSLs are at the forefront of its application. AI and machine learning tools are now integral to processing complex data sets, streamlining literature reviews, and identifying evidence gaps. As stated by Dr. William Soliman in a 2025 panel discussion, the potential for AI to support clinical trial design and optimize stakeholder interactions is vast, with projected industry-wide investments reaching $200 billion by 2030.

However, this transformation is not without risk. Ethical AI use is a critical concern. Poorly designed AI systems can introduce bias, make unsafe recommendations, or misinform decision-making processes, especially in high-stakes areas including healthcare access and claims adjudication. Companies such as ACMA have responded by developing proprietary tools (Medaffairs AI) that offer field medical teams tailored and reliable AI solutions. These tools must be applied with transparency and oversight to ensure they enhance, rather than compromise, the trust and efficacy of MSL activities.

3. Harmonization and Standardization of Medical Affairs Teams

Standardization across medical affairs is another growing imperative. As organizations grow in complexity and scope, the need for a unified, competency-based structure becomes essential. Certification programs, such as ACMA’s Board Certified Medical Affairs Specialist (BCMAS), offer a way to establish minimum standards across field teams and improve overall credibility with healthcare professionals.

Post-COVID, public scrutiny of the pharmaceutical industry has intensified, increasing the demand for transparency and consistency. Stakeholders, including healthcare providers and regulators, expect uniformly high standards of knowledge and ethical behavior. Standardized training reduces compliance risk, enhances cross-functional collaboration, and improves key opinion leader (KOL) engagement. Notably, ACMA data shows that standardized training improves compliance by 30% and effectiveness by up to 35%, translating to potential savings of over $160 million annually in large organizations.

4. Expanding Role of Real-World Evidence

The application of real-world evidence (RWE) is rapidly reshaping how drugs are developed and evaluated post-approval. MSLs play a pivotal role in translating RWE into actionable insights for both internal and external stakeholders. This trend aligns with increasing regulatory interest in RWE to support label expansions and evaluate product effectiveness outside controlled clinical trial settings.

RWE enhances decision-making by offering insights into treatment outcomes, adherence patterns, and unmet medical needs across broader, more diverse populations. MSLs must be adept at interpreting RWE, designing post-marketing studies, and effectively communicating findings to support clinical and regulatory goals.

5. Patient-Centric Engagement and Advocacy Collaboration

Patient-centricity has become the leading guiding principle within the healthcare field. MSLs are now expected to bridge the gap between pharmaceutical companies and patient communities, primarily through collaboration with patient advocacy organizations. Direct engagement with patients is typically restricted, but MSLs can gather insights from advocacy groups to shape clinical development strategies and educational initiatives.

This focus aligns with broader trends in digital health and personalized medicine. Patients today are more empowered and informed, and their involvement in healthcare decisions continues to grow. MSLs must then integrate patient perspectives into the development of materials, strategies, and messaging that resonate with real-world needs.

Evolving Skills and Career Pathways

As the role of the MSL expands, so does the skill set required. Beyond scientific acumen, today’s MSLs require competencies in business strategy, compliance, digital tools, and stakeholder engagement. Those entering the MSL space from backgrounds in research & development, scientific writing, or academia must quickly develop capabilities in territory management, stakeholder communication, and insight generation.

The market also demands adaptability. MSLs must manage dynamic priorities, shifting stakeholder expectations, and complex data landscapes. Companies now value certifications and training that provide soft skills and business understanding in addition to scientific expertise.

The Future Outlook: Personalization, AI Integration, and Organizational Agility

Looking ahead, trends in personalized medicine and AI integration will continue to shape the MSL landscape. AI tools will increasingly support data analysis, clinical trial optimization, and stakeholder targeting. However, these tools will complement, not replace, the human insight and relationship-building skills that define effective MSLs.

Additionally, the pharmaceutical industry must overcome existing gaps in how field insights are utilized. While field teams often collect valuable information, organizational barriers frequently prevent these insights from influencing strategic decisions. Moving toward agile, tech-informed operating models will assist companies in responding more effectively to market shifts and emerging scientific developments.

While in-person engagement remains preferred for establishing strong relationships, the future will likely involve a hybrid approach. The next generation of healthcare providers is more open to virtual interactions, and companies must evolve to meet these changing preferences while ultimately maintaining the quality and depth of their educational exchanges.